Development of a prognostic nomogram and risk stratification system for upper thoracic esophageal squamous cell carcinoma

Background The study aimed to develop a nomogram model to predict overall survival (OS) and construct a risk stratification system of upper thoracic esophageal squamous cell carcinoma (ESCC). Methods Newly diagnosed 568 patients with upper ESCC at Fujian Medical University Cancer Hospital were taken as a training cohort, and additional 155 patients with upper ESCC from Sichuan Cancer Hospital Institute were used as a validation cohort. A nomogram was established using Cox proportional hazard regression to identify prognostic factors for OS. The predictive power of nomogram model was evaluated by using 4 indices: concordance statistics (C-index), time-dependent ROC (ROCt) curve, net reclassification index (NRI) and integrated discrimination improvement (IDI). Results In this study, multivariate analysis revealed that gender, clinical T stage, clinical N stage and primary gross tumor volume were independent prognostic factors for OS in the training cohort. The nomogram based on these factors presented favorable prognostic efficacy in the both training and validation cohorts, with concordance statistics (C-index) of 0.622, 0.713, and area under the curve (AUC) value of 0.709, 0.739, respectively, which appeared superior to those of the American Joint Committee on Cancer (AJCC) staging system. Additionally, net reclassification index (NRI) and integrated discrimination improvement (IDI) of the nomogram presented better discrimination ability to predict survival than those of AJCC staging. Furthermore, decision curve analysis (DCA) of the nomogram exhibited greater clinical performance than that of AJCC staging. Finally, the nomogram fairly distinguished the OS rates among low, moderate, and high risk groups, whereas the OS curves of clinical stage could not be well separated among clinical AJCC stage. Conclusion We built an effective nomogram model for predicting OS of upper ESCC, which may improve clinicians’ abilities to predict individualized survival and facilitate to further stratify the management of patients at risk.

[1]  Yushan Chen,et al.  Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer , 2021, BMC Cancer.

[2]  Jun Liang,et al.  Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial , 2021, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  Jinming Yu,et al.  A nomogram for the predicting of survival in patients with esophageal squamous cell carcinoma undergoing definitive chemoradiotherapy , 2021, Annals of translational medicine.

[5]  F. van Leth,et al.  Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings , 2020, Nature medicine.

[6]  Zaibo Jiang,et al.  Risk Stratification Based on Chronic Liver Failure Consortium Acute Decompensation Score in Patients With Child‐Pugh B Cirrhosis and Acute Variceal Bleeding , 2020, Hepatology.

[7]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[8]  Y. Ba,et al.  Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. , 2020, The Lancet. Oncology.

[9]  Shulin Chen,et al.  The prognostic value of integration of pretreatment serum amyloid A (SAA)–EBV DNA (S-D) grade in patients with nasopharyngeal carcinoma , 2020, Clinical and Translational Medicine.

[10]  A. Futreal,et al.  Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma , 2019, Nature Communications.

[11]  Mingjun Jiang,et al.  A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer , 2019, Cancer Chemotherapy and Pharmacology.

[12]  J. Aho,et al.  Additional Patient Factors may Predict Survival in Esophageal Cancer Better than TMN Alone After Esophagectomy , 2019, Annals of Surgical Oncology.

[13]  Quan P. Ly,et al.  Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  Q. Xue,et al.  Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy , 2019, Annals of Surgical Oncology.

[15]  W. Ni,et al.  Proposed revision of the 8th edition AJCC clinical staging system for esophageal squamous cell cancer treated with definitive chemo-IMRT based on CT imaging , 2019, Radiation oncology.

[16]  R. van Hillegersberg,et al.  Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer. , 2018, The Annals of thoracic surgery.

[17]  S. Jiao,et al.  A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy , 2018, Journal of Immunotherapy for Cancer.

[18]  J. Wu,et al.  A new clinical staging system for esophageal cancer to predict survival after definitive chemoradiation or radiotherapy. , 2018, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[19]  D. van Klaveren,et al.  Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery , 2016, The British journal of surgery.

[20]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[21]  E. Steyerberg,et al.  [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.

[22]  Z. Liao,et al.  Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus. , 2010, The Annals of thoracic surgery.

[23]  N. Obuchowski,et al.  Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures , 2010, Epidemiology.

[24]  Nancy R Cook,et al.  Advances in Measuring the Effect of Individual Predictors of Cardiovascular Risk: The Role of Reclassification Measures , 2009, Annals of Internal Medicine.

[25]  Yijiang Chen,et al.  Factors predictive of prognosis after esophagectomy for squamous cell cancer. , 2009, The Journal of thoracic and cardiovascular surgery.

[26]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[27]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[28]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[29]  Guoqing Diao,et al.  Estimation of time‐dependent area under the ROC curve for long‐term risk prediction , 2006, Statistics in medicine.

[30]  N. Obuchowski.  Receiver operating characteristic curves and their use in radiology. , 2003, Radiology.

[31]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[32]  D. Joseph,et al.  Factors influencing outcome following radio-chemotherapy for oesophageal cancer , 1996 .

[33]  J. Habbema,et al.  The Measurement of Performance in Probabilistic Diagnosis , 1978, Methods of Information in Medicine.